Health
GSK Asthma Drug Shows Promise in Treating Chronic Lung Disease
This article is for subscribers only.
GSK Plc’s blockbuster asthma drug showed positive results when used as a treatment for another chronic lung condition, potentially opening up a new avenue of growth for the medicine.
The UK drug company said an advanced trial of Nucala in some adults with chronic obstructive pulmonary disease showed a statistically significant and clinically meaningful reduction in the rate of moderate and severe flare ups versus the placebo. Patients were treated for as long as two years.